^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    2aG4

    i
    Other names: 2aG4, anti-phosphatidylethanolamine monoclonal antibodies
    Associations

    News

    Trials
    Company:
    Avid Bioservices
    Drug class:
    Phosphatidylserine receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    5years
    [VIRTUAL] Inhibiting Growth of Human Triple-Negative Breast Cancer Cells by Activating Mutant p53 Protein Alone or in Combination With a Phosphatidylserine-Targeting Antibody (ENDO 2021)
    A third group was given both APR-246 and 2aG4 using the same doses above. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
    Combination therapy • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    TP53 mutation • TP53 expression • BAX expression • VEGFA expression
    |
    eprenetapopt (APR-246) • 2aG4